iShares Industrial Bond ETF ENGN 深 滬
等待開盤 08-15 09:30:00 美东时间
3.61
-0.010
-0.28%
華盛通- 最 高3.72
- 今 開3.6177
- 成交量 2.01万股
- 最 低 3.5165
- 昨 收 3.62
- 總市值 1.84亿
- 52周最高 11.00
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 2.65
- 委 比 -48.10%
- 總股本 5110.52万
- 歷史最高 43.00
- 量 比 0.50
- 振 幅 5.62%
- 歷史最低 2.65
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognizes the potential of detalimogene to address significant unmet needenGene Holdings Inc.
06-25 20:12
enGene Holdings Reports Q2 2025 Financial Results
Engene Holdings Inc. ( ($ENGN) ) has released its Q2 earnings. Here is a breakd...
06-13 11:53
enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from
06-12 20:13
enGene Holdings Approves 2025 Employee Stock Purchase Plan
enGene Holdings ( ($ENGN) ) just unveiled an announcement. On June 10, 2025, en...
06-11 05:49
enGene Holdings CMO Resignation Announced
enGene Holdings ( ($ENGN) ) has provided an announcement. On June 3, 2025, Dr. ...
06-04 20:59
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.38) by 5.8 percent. This is a 99.03 percent increase over losses of $(151.22) per share from
2024-12-20 05:12
enGene Holdings: Strategic Differentiation Justifies Buy Rating Amidst Competitive Data
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rat...
2024-12-06 17:46
enGene announces $60M private placement financing
enGene Holdings (NASDAQ:ENGN) has announced that it has agreed to sell 6.76M of its common shares at a price per share of $8.90. enGene anticipates the gross proceeds to be ~$60M and, intends to use t...
2024-10-25 20:10
